Indeed, clinical trials with activated γδ T cells have shown promising results for the

treatment of solid tumors [57], lymphoma [54], www.selleckchem.com/products/Trichostatin-A.html renal carcinoma [58], and lung cancer [55]. Humans have a less varied repertoire of γδ T cells as compared with mice; indeed, the majority of human γδ T cells are of either the Vδ1+ or Vδ2+ subclasses of γδ T cells. The majority of human peripheral blood γδ T cells are of the Vδ2+ subset, while the Vδ1+ cells account for the bulk of γδ T cells found at the epithelium. Similar to the murine γδ TCR, the human γδ TCR has been shown to be activated in an MHC-independent manner. Vγ9Vδ2+ T cells are rapidly activated by (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) and to a lesser extent by isopentenyl pyrophosphate (IPP), both metabolites of the isoprenoid biosynthesis pathway in bacteria and protozoa [59-62]. Furthermore, neonatal Vγ9Vδ2+ T cells produce IL-17, but not IFN-γ, following stimulation with IL-23 and the aminobisphosphonate zoledronate [60]. In addition, it selleck kinase inhibitor has

been demonstrated that combinations of IL-1, IL-23, IL-6, and TGF-β promote IL-17 production from RORγt+ Vγ9Vδ2+ T cells [25, 63-65]. Of note, mice do not appear to express a homologue of the Vγ9Vδ2 TCR. Other stimuli for human γδ T cells are zoldronate, IL-2, IL-18, and anti-γδ TCR antibodies [54-56, 66]. The anti-γδ TCR antibody GL3 appears

to induce more sustained proliferation of both Vδ2 and Vδ1 human γδ T cells than phosphoantigen-expanded human γδ T cells [54]. ILCs develop from hematopoietic precursors and have common phenotypic characteristics with T lymphocytes, yet they lack expression of specific antigen receptors (Fig. 2). All ILCs depend on IL-7 for their development. Evidence is emerging that these cells differentiate into subsets Thalidomide capable of producing effector cytokines similar to the different T helper cell subsets, except it appears that ILCs are able to respond more rapidly to inflammatory stimuli (as reviewed in [67]). ILCs are a heterogeneous population of cells, often increased in number at barrier surfaces, where they play a protective role in immune responses to infection [68]; however, there is emerging evidence that dysregulation of the IL-17-producing ILC subset drives intestinal inflammation, leading to colitis [3]. Id2 (inhibitor of DNA binding-2) is a helix-loop-helix transcription factor that lacks DNA-binding domains and heterodimerizes with E-box proteins to act as a critical regulator of gene transcription [69]. It is a key regulatory protein essential for a wide range of developmental and cellular processes and is essential for the development of all ILC subsets [70-72].